Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 341-352 , June 2006

Advances in prevention and treatment of hepatic disorders following hematopoietic cell transplantation

References 

  1. Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology. 2005;41:345–352
  2. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In:  Blume K,  Forman SJ,  Appelbaum F editor. Thomas' Hematopoietic Cell Transplantation. 3rd edn. Malden, MA: Blackwell Publishing Inc.; 2004;p. 769–810
  3. Lau GKK, Strasser SI, McDonald GB. Hepatitis virus infections in patients with cancer. In:  Wingard JR,  Bowden RA editor. Management of Infection in Oncology Patients. London, UK: Martin Dunitz; 2003;p. 321–342
  4. Deleve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venocclusive disease). Seminars in Liver Disease. 2002;22:27–41
  5. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101:2043–2048
  6. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578–1582
  7. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection after bone marrow transplantation: a cohort study with 10 year follow-up. Hepatology. 1999;29:1893–1899
  8. McDonald GB, McCune JS, Batchelder A, et al. Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clinical Pharmacology & Therapeutics. 2005;78:298–308
  9. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology. 2000;60:143–154
  10. Meresse V, Hartmann O, Vassal G, et al. Risk factors of hepatic venocclusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant. 1992;10:135–141
  11. Bornhauser M, Storer B, Slattery J, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003;102:820–826
  12. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood. 2004;103:76–82
  13. Carreras E, Granena A, Navasa M, et al. Transjugular liver biopsy in bone marrow transplantation. Bone Marrow Transplant. 1993;11:21–26
  14. Shulman HM, Gooley T, Dudley MD, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation. 1995;59:1015–1022
  15. Bearman SI, Anderson GL, Mori M, et al. Venocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. Journal of Clinical Oncology. 1993;11:1729–1736
  16. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplant with severe veno-occlusive disease and multi-system organ failure: response without significant toxicity in a high risk population and factors predictive of outcome. Blood. 2002;100:4337–4343
  17. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology. 1993;11:1652–1660
  18. Green RM, Beier D, Gollan JL. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology. 1996;111:193–198
  19. Shulman HM, Sharma P, Amos D, et al. A coded histologic study of hepatic graft-versus-host disease after human marrow transplantation. Hepatology. 1988;8:463–470
  20. Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-vs-host disease of the liver: presentation as an acute hepatitis. Hepatology. 2000;32:1265–1271
  21. Akpek G, Boitnott JK, Lee LA, et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood. 2002;100:3903–3907
  22. Saunders MD, Shulman HM, Murakami CS, et al. Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. American Journal of Surgical Pathology. 2000;24:1004–1008
  23. Ko CW, Murakami C, Sekijima JH, et al. Chemical composition of gallbladder sludge in patients after marrow transplantation. American Journal of gastroenterology. 1996;91:1207–1210
  24. Jardines LA, O'Donnell MR, Johnson DL, et al. Acalculous cholecystitis in bone marrow transplant patients. Cancer. 1993;71:354–358
  25. Ko CW, Gooley T, Schoch HG, et al. Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis. Bone Marrow Transplant. 1997;20:1081–1086
  26. Cabana MD, Alavi A, Berlin JA, et al. Morphine-augmented hepatobiliary scintigraphy: a meta-analysis. Nuclear Medicine Communications. 1995;16:1068–1071
  27. Murakami CS, Louie W, Chan GS, et al. Biliary obstruction in hematopoietic cell transplant recipients: an uncommon diagnosis with specific causes. Bone Marrow Transplant. 1999;23:921–927
  28. Fried RH, Murakami CS, Fisher LD, et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Annals of International Medicine. 1992;116:624–629
  29. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biology of Blood and Marrow Transplantation. 2000;6:44–49
  30. Blanke C, Clark C, Broun ER, et al. Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections. The American Journal of Medicine. 1995;99:326–328
  31. Yagi T, Karasuno T, Hasegawa T, et al. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: importance of empiric therapy with acyclovir. Bone Marrow Transplant. 2000;25:1003–1005
  32. Bordigoni P, Carret AS, Venard V, et al. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clinical Infectious Diseases. 2001;32:1290–1297
  33. Lau GK, He M-L, Fong DYT, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702–709
  34. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1—>3)-beta-d-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. Journal of Clinical Microbiology. 2004;42:2733–2741
  35. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. Journal of Infectious Diseases. 2004;190:641–649
  36. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clinical Infectious Diseases. 2004;39:199–205
  37. Navari RM, Sullivan KM, Springmeyer SC, et al. Mycobacterial infections in marrow transplant patients. Transplantation. 1983;36:509–513
  38. Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103:1618–1624
  39. Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood. 1999;93:3259–3266
  40. Andreoni KA, Lin JI, Groben PA. Liver transplantation 27 years after bone marrow transplantation from the same living donor. New England Journal of Medicine. 2004;350:2624–2625
  41. Hassan M, Ljungman P, Ringden O, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 2000;25:915–924
  42. Ruutu T, Eriksson B, Remes K, et al. Nordic Bone Marrow Transplantation G. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100:1977–1983
  43. Deschenes M, Laneuville P. Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection. Hepatology. 2004;39:867–868
  44. Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology. 2002;122:614–624
  45. Carpenter PA, Huang ML, McDonald GB. Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale. Blood. 2002;99:4245–4246
  46. Anttila VJ, Lamminen AE, Bondestam S, et al. Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. European Journal of Haematology. 1996;56:82–87
  47. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: An autopsy study of 355 patients. Medicine (Baltimore). 1998;77:246–254
  48. Oliver MR, Van Voorhis WC, Boeckh M, et al. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clinical Infectious Diseases. 1996;22:521–524

PII: S1521-6926(05)00122-2

doi: 10.1016/j.beha.2005.11.008

Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 341-352 , June 2006

Article Tools